Amy Peterson

Biography
Amy Peterson has decades of hands-on experience in oncology drug development from target identification through global approvals. Her work spans big to small companies, including Exelixis, CytomX and BeiGene, Medivation and Genentech. She has contributed to dozens of approvals spanning solid and liquid tumors across all lines of therapy. Frustrated with the high costs, long timelines and low success rates of drug approvals, she and Suman Bhattacharya, PhD, co-founded AuraClinical designed to encode deep drug development knowledge into an AI-native end to end platform that connects, collects, curates and communicates data from every single workstream necessary to initiate, execute and report clinical trial outcomes. Instead of fixing one study, one program, one company at a time, one human at a time, AuraClinical leverages the scalability, speed and capacity of AI to fix thousands of studies across hundreds of companies, getting to better outcomes faster.